China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Adebrelimab combined with NALIRIFOX for neoadjuvant therapy of resectable pancreatic cancer'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133371
Registration Time: 2026/09/24
Type: Interventional study
Primary Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=245719
Published by HT Digital Content Services with permission from Health Daily Digest....